Design, Synthesis, Structural Studies, Biological Evaluation, and Computational Simulations of Novel Potent AT1 Angiotensin II Receptor Antagonists Based on the 4-Phenylquinoline Structure

Journal of Medicinal Chemistry

Volumn 47, Issue 10, 2004, Pages 2574-2586

  Cappelli, Andrea ^a   Mohr, Gal La Pericot ^a   Gallelli, Andrea ^a   Rizzo, Milena ^b   Anzini, Maurizio ^a   Vomero, Salvatore ^a   Mennuni, Laura ^c   Ferrari, Flora ^c   Makovec, Francesco ^c   Menziani, M Cristina ^d   De Benedetti, Pier G ^d   Giorgi, Gianluca ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c Rotta Research Laboratorium   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [(5,7 DIMETHYL 2 ETHYL 3H IMIDAZO[4,5 B]PYRIDIN 3 YL)METHYL]PHENYL] 3 (2H TETRAZOL 5 YL)QUINOLINE; ANGIOTENSIN II [1 SARCOSINE 8 ISOLEUCINE]; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; IODINE 125; LIGAND; LOSARTAN; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; LIVER MEMBRANE; MALE; MUSCLE CONTRACTION; NONHUMAN; RABBIT; RAT; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA, THORACIC; BINDING, COMPETITIVE; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; IMIDAZOLES; ISOMETRIC CONTRACTION; LIGANDS; LIVER; MALE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUSCLE, SMOOTH, VASCULAR; PURINES; PYRIDINES; QUINOLINES; RABBITS; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLES;

EID: 2342557311     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm031100t     Document Type: Article

References (43)

1. De Gasparo, M.; Catt, K. J.; Inagami, T.; Wright, J. W.; Unger, T. International Union of Pharmacology. XXIII. The Angiotensin II Receptors. Pharmacol. Rev. 2000, 52, 415-472 and references therein.
2. Cockcroft, J. R.; Sciberras, D. G.; Goldberg, M. R.; Ritter, M. J. Comparison of Angiotensin-Converting Enzyme Inhibition with Angiotensin II Receptor Antagonism in the Human Forearm. J. Cardiovasc. Pharmacol. 1993, 22, 579-584.
3. Unger, T. The Role of the Renin-Angiotensin System in the Development of Cardiovascular Disease. Am. J. Cardiol. 2002, 89(suppl), 3A-10A.
4. Inoue, Y.; Nakamura, N.; Inagami, T. A Review of Mutagenesis Studies of Angiotensin II Type 1 Receptor, the Three-Dimensional Receptor Model in Search of the Agonist Binding Site and the Hypothesis of a Receptor Activation Mechanism. J. Hypertens. 1997, 15, 703-714.
5. (a) Wexler, R. R.; Greenlee, W. J.; Irvin, J. D.; Goldberg, M. R. Prendergast, K.; Smith, R. D.; Timmermans, P. B. M. W. M. Nonpeptide Angiotensin II Receptor Antagonists: The Next Generation in Antihypertensive Therapy. J. Med. Chem. 1996, 39, 625-656.
6. (b) Schmidt, B.; Schieffer, B. Angiotensin II AT1 Receptor Antagonista. Clinical Implications of Active Metabolites. J. Med. Chem. 2003, 46, 2261-2270, and references therein.
7. (a) Mantlo, N. B.; Chakravarty, P. K.; Ondeyka, D. L.; Siegl, P. K. S.; Chang, R. S.; Lotti, V. J.; Faust, K. A.; Chen, T.-B.; Schorn, T. W.; Sweet, C. S.; Emmert, S. E.; Patchett, A. A.; Greenlee, W. J. Potent, Orally Active Imidazo[4,5-b]pyridine-Based Angiotensin II Receptor Antagonists. J. Med. Chem. 1991, 34, 2919-2922.
8. (b) Kim, D.; Mantlo, N. B.; Chang, R. S.; Kivlighn, S. D.; Greenlee, W. J. Evaluation of Heterocyclic Acid Equivalents as Tetrazole Replacements in Imidazopyridine-Based Nonpeptide Angiotensin II Receptor Antagonists. Bioorg. Med Chem. Lett. 1994, 4, 41-44.
9. Reitz, D. B.; Penick, M. A.; Reinhard, E. J.; Cheng, B. K.; Olins, G. M. ; Corpus, V. M.; Palomo, M. A.; McGraw, D. E.; McMahon, E. G. 1H-1,2,4-Triazole Angiotensin II Receptor Antagonists: N-Phenylpyridinylmethyl and N-Pyridinylphenyhnethyl Analogues of SC-50560. Bioorg. Med. Chem. Lett. 1994, 4, 99-104.
10. Mantlo, N. B.; Chang, R. S. L.; Siegl, P. K. S. Angiotensin II Receptor Antagonists Containing a Phenylpyridine Element. Bioorg. Med. Chem. Lett. 1993, 3, 1693-1696.
11. 1 receptor antagonists show limited oral bioavailability (eprosartan 13%, valsartan 25%, losartan 33%, candesartan 42%, telmisartan 50%, irbesartan 60-80%). [(a) Israili, Z. H. Clinical Pharmacokinetics of Angiotensin II (AT1) Receptor Blockers in Hypertension. J. Hum. Hypertens. 2000, 14 suppl 1, S73-86.
12. (b) Brunner, H. R. The New Angiotensin II Receptor Antagonist, Irbesartan. Am. J. Hypertens. 1997, 10, 311S-317S.)] Furthermore, losartan exhibiting highly variable oral bioavailability is transported by P-glycoprotein, while its carboxylic acid metabolite is not a P-glycoprotein substrate; see Soldner, A.; Benet, L. Z.; Mutschler, E.; Christians, U. Active Transport of the Angiotensin-II Antagonist Losartan and its Main Metabolite EXP 3174 Across MDCK-MDR1 and Caco-2 Cell Monolayers. Br. J. Pharmacol. 2000, 129, 1235-1243.
13. (b) Brunner, H. R. The New Angiotensin II Receptor Antagonist, Irbesartan. Am. J. Hypertens. 1997, 10, 311S-317S.)] Furthermore, losartan exhibiting highly variable oral bioavailability is transported by P-glycoprotein, while its carboxylic acid metabolite is not a P-glycoprotein substrate; see Soldner, A.; Benet, L. Z.; Mutschler, E.; Christians, U. Active Transport of the Angiotensin-II Antagonist Losartan and its Main Metabolite EXP 3174 Across MDCK-MDR1 and Caco-2 Cell Monolayers. Br. J. Pharmacol. 2000, 129, 1235-1243.
14. (a) Senanayake, C. H.; Fredenburgh, L. E.; Reamer, R. A.; Liu, J.; Roberts, F. E.; Humphrey, G.; Thompson, A. S.; Larsen, R. D.; Verhoeven, T. R.; Reider, P. J.; Shinkai, I. New Approach to the Imidazolutidine Moiety of MK-996. Heterocycles 1996, 42, 821-830.
15. (b) Chakravarty, P. K.; Greenlee, W. J.; Mantlo, N. B.; Patchett, A. A.; Walsh, T. F. Substituted Imidazo-Fused 6-membered Heterocycles as Angiotensin II Antagonists. U. S. Patent 5,332,744, 1994. Chem. Abstr. 123, 143911.
16. Echavarren, A. M.; Stille, J. K. Palladium-Catalyzed Coupling of Aryl Triflates with Organostannanes. J. Am. Chem. Soc. 1987, 109, 5478-5486.
17. Marck, G.; Villiger, A.; Buchecker, R. Aryl Couplings with Heterogeneous Palladium Catalysts. Tetrahedron Lett. 1994, 35, 3277-3280.
18. Walsh, D. A. The Synthesis of 2-Aminobenzophenones. Synthesis 1980, 677-688.
19. Tawada, H.; Harcourt, M.; Kawamura, N.; Kajino, M.; Ishikawa, E.; Sugiyama, Y.; Ikeda, H.; Meguro, K. Novel Acyl-CoA: Cholesterol Acyltransferase Inhibitors. Synthesis and Biological Activity of 3-Quinolylurea Derivatives. J. Med. Chem. 1994, 37, 2079-2084.
20. 3 Receptor Antagonists Based on the Arylpiperazine Skeleton: Synthesis, Structure, Biological Activity, and Comparative Molecular Field Analysis Studies. J. Med. Chem. 1995, 38, 2692-2704.
21. Chakravarty, P. K.; Maccross, M.; Mantlo, N. B.; Walsh, T. F. Preparation and Use of N-Benzylareneimidazole Derivatives as Angiotensin II Antagonists. U. S. Patent 5,128,327, 1992. Chem. Abstr. 123, 228187.
22. Chang, R. S. L.; Siegl, P. K. S.; Clineschmidt, B. W.; Mantlo, N. B.; Chakravarty, P. K.; Greenlee, W. J.; Patchett, A. A.; Lotti, V. J. In vitro Pharmacology of L-158, 809, a New Highly Potent and Selective Angiotensin II Receptor Antagonists. J. Pharmacol. Exp. Ther. 1992, 262, 133-138.
23. Naphthalene derivative 4a was described in a patent application (see Suzuki, K.; Fujiwara, S.; Machii, D.; Ochifuji, N.; Takai, H.; Oono, T.; Furuta, S.; Yamada, K. Preparation of Imidazopyridines and Analogs as Angiotensin II Antagonists. Jpn. Kokai Tokkyo Koho JP 06 92,939, 1994. Chem. Abstr. 121, 179581 and Fujiwara, S.; Takai, H.; Mizukami, T.; Myaji, H.; Sato, S.; Oomori, T.; Nukui, E. Preparation of N-[4-(4-Quinolinyl)benzyl]-benzimidazole Derivatives as Immunosuppressants. Jpn. Kokai Tokkyo Koho JP 06,340,658, 1994. Chem. Abstr. 122, 239702) and resynthesized in our laboratory as a reference compound for our quinoline derivatives.
24. Naphthalene derivative 4a was described in a patent application (see Suzuki, K.; Fujiwara, S.; Machii, D.; Ochifuji, N.; Takai, H.; Oono, T.; Furuta, S.; Yamada, K. Preparation of Imidazopyridines and Analogs as Angiotensin II Antagonists. Jpn. Kokai Tokkyo Koho JP 06 92,939, 1994. Chem. Abstr. 121, 179581 and Fujiwara, S.; Takai, H.; Mizukami, T.; Myaji, H.; Sato, S.; Oomori, T.; Nukui, E. Preparation of N-[4-(4-Quinolinyl)benzyl]-benzimidazole Derivatives as Immunosuppressants. Jpn. Kokai Tokkyo Koho JP 06,340,658, 1994. Chem. Abstr. 122, 239702) and resynthesized in our laboratory as a reference compound for our quinoline derivatives.
25. Carini, D. J.; Duncia, J. V.; Aldrich, P. E.; Chiu, A. T.; Johnson, A. L.; Pierce, M. E.; Price, W. A.; Santella, J. B., III; Wells, G. J.; Wexler, R. R.; Wong, P. C.; Yoo, S.-E.; Timmermans, P. B. M. W. M. Nonpeptide Angiotensin II Receptor Antagonists: The Discovery of a Series of N-(Biphenylmethyl)imidazoles as Potent, Orally Active Antihypertensives. J. Med. Chem. 1991, 34, 2525-2547.
26. The different prototropic tautomerism behavior of the heterocyclic amino derivatives with respect to the corresponding hydroxy derivatives has been discussed by Katritzky, A. R. and co-workers (Katritzky, A. R.; Karelson, M.; Harris, P. A. Prototropic Tautomerism of Heteroaromatic Compounds. Heterocycles, 1991, 32, 329-369). These authors pointed out that 2-aminopyridine exists predominantly in the amino-form, while 2-pyridones exist in the oxo-form.
27. Kurup, A.; Garg, R.; Carini, D. J.; Hansch, C. Comparative QSAR: Angiotensin II Antagonists. Chem. Rev. 2001, 101, 2727-2750.
28. Karelson, M.; Lobanov, V. S.; Katritzky, A. R. Quantum-Chemical Descriptors in QSAR/QSPR Studies. Chem. Rev. 1996, 96, 1027-1043.
29. Beukers, M. W.; Kristiansen, K.; Ijzerman, A. P.; Edvardsen, Ø. TinyGRAP Database: a Bioinformatics Tool to Mine G Protein-Coupled Receptor Mutant Data. Trends Pharmacol. Sci. 1999, 20, 475-477.
30. Henderson, R.; Baldwin, J.; Ceska, T. H.; Zemlin, F.; Beckmamn, E.; Downing, K. Model of the Structure of Bacteriorhodopsin Based on High-Resolution Electron Cryomicroscopy. J. Mol. Biol. 1990, 213, 899-919.
31. Baldwin, J. M. The Probable Arrangement of the Helices in G Protein-Coupled Receptors. EMBO J. 1993, 12, 1693-1703.
32. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal Structure of Rhodopsin: A G-Protein-Coupled Receptor. Science, 2000, 289, 739-745
33. Wilkes, B. C.; Masaro, L.; Schiller, P. W.; Carpenter, K. A. Angiotensin II vs its Type I Antagonists: Conformational Requirements for Receptor Binding Assessed from NMR Spectroscopic and Receptor Docking Experiments. J. Med. Chem. 2002, 45, 4410-4418.
34. Robertson, M. J.; Cunoosamy, M. P.; Clark, K. L. Effects of Peptidase Inhibition on Angiotensin Receptor Agonist and Antagonist Potency in Rabbit Isolated Thoracic Aorta. Br. J. Pharmacol. 1992, 106, 166-172.
35. Ji, H.; Zheng, W.; Zhang, Y.; Catt, K. J.; Sandberg, K. Genetic Transfer of a Nonpeptide Antagonist Binding Site to a Previously RT Unresponsive Angiotensin Receptor. Proc. Natl. Acad. Sci. U.S.A. 1925, 92, 9240-9244.
36. Sheldrick, G. M. SHELXS-97, Rel. 97-2, Program for X-ray data diffraction, Gottingen University, 1997.
37. Sheldrick, G. M. SHELXL-97, Rel. 97-2, Program for X-ray data diffraction, Gottingen University, 1997.
38. Dewar, M. J. S.; Zoebisch, E. G.; Healey, E. F.; Stewart, J. J. P. AMI: A New General Purpose Quantum Mechanical Molecular Model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
39. Sali, A.; Blundell, T. L. Comparative Protein Modeling by Satisfaction of Spatial Restraints. J. Mol. Biol. 1993, 234, 779-815.
40. Thompson, J. D.; Higgins, D. G.; Gibson, T.; Clustal, W. Improving the Sensitivity of Progressive Multiple Sequence Alignment through Sequence Weighting, Position-Specific Gap Penalties and Weight Matrix Choice. J. Nucleic Acids Res. 1994, 22, 4673-4680.
41. Quanta98, 1998 Accelrys, San Diego, CA.
42. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: a Program for Macromolecular Energy Minimization and Dynamics Calculations. J. Comput. Chem. 1983, 4, 187-217.
43. van Gunsteren, W. F.; Berendsen, J. C. Algorithms for Macromolecular Dynamics and Constraint Dynamics. Mol. Phys. 1977, 34, 1311-1327.